A phase IIb trial of nangibotide in septic shock has demonstrated preliminary signs of efficacy in a subset of biomarker-defined patients and provided its developer, Inotrem SA, with a dataset that will inform the design of a registration program for the drug. Subject to agreement from regulatory agencies, the company aims to move the triggering receptor on myeloid cells 1 inhibitor into a first phase III trial in early 2024. “We should have a clearer picture by the beginning of the second next year,” CEO Sven Zimmermann told BioWorld.
CSL Ltd. subsidiary Seqirus inked a $30.1 million deal with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and evaluate two influenza A subtype H2Nx (avian flu) vaccines in a phase I trial.
CSL Ltd. subsidiary Seqirus inked a $30.1 million deal with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop and evaluate two influenza A subtype H2Nx (avian flu) vaccines in a phase I trial.
Finding a vaccine that provides universal protection against seasonal influenza remains a public health priority. Although influenza neuraminidase (NA) undergoes slower antigenic changes than hemagglutinin (HA) and therefore constitutes a desirable vaccine target, NA standalone vaccination strategies present a limited breadth of NA immunity.
Sorrento Therapeutics Inc. has published data on the identification, in vitro binding and neutralizing activity of a novel monoclonal antibody (MAb), STI-5041, against the SARS-CoV-2 WA-1 strain as well as the alpha and beta variants from their G-MAB library screening.
The University of Arizona has divulged nonstructural protein 3 (Nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
CEPI, the Coalition for Epidemic Preparedness Innovations, will provide seed funding of up to $4.8 million to Intravacc BV to advance the development of a broadly protective betacoronavirus vaccine candidate, which can be delivered intranasally.
Covira Inc., a spinout from The University of Chicago, has closed its first dilutive funding via an oversubscribed $1.0 million seed round after raising $9.1 million of nondilutive funding.
Revelation Biosciences Inc. has entered into an exclusive worldwide license agreement with Vanderbilt University to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD) for treating or preventing infections.
Virtici LLC has been granted a Small Business Innovation Research (SBIR) award by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) to advance VTC-886, a first-in-class small molecule for the prevention of Porphyromonas gingivalis infection.
RSS
